database > company
ScyFIX
HCID Member | Medical Devices & Tech
570 W 78TH ST # 2001
Chanhassen, MN 55317 USA
phone:612-964-6500
fax:952-975-0616
Symbol Private
Founded 2002
Employees 10
          www.scyfix.org
Research Sector Medical Devices & Tech
Summary Description
Micro-current Neuromodulation for Recovery of Diseased Eye Tissue
Management
Thomas W. Harold, Founder, Chief Executive Officer; Darrel DeMello, President; Stefan Bengtsson, Managing Director
Keywords
Micro-Current Neuromodulation/Stimulation, Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, Glaucoma, CMV-Retinitis

Comment | Printable Version | Modify profile Apr. 28, 2010

Description
ScyFIX is developing sight-saving technologies for people suffering from degenerative eye diseases for which there are currently no cures or therapies. ScyFIX offers the only patented micro-current neuromodulation/stimulation device for the treatment of macular degeneration, Stargardt's disease, retinitis pigmentosa and other degenerative eye diseases.
Products / Services
The ScyFIX 700 micro current neuromodulation/stimulation device facilitates increased brightness, decreased fogginess, improved visual acuity, enhanced color perception and reduction of blind spots. Micro-current stimulation has also been proven to expand the visual fields of individuals diagnosed with retinitis pigmentosa. The ISO 13485 medical directive certification was recieved in February, 2009.
Technology / Differentiation
Research suggests that the ScyFIX electrical neuromodulation/stimulation device approximates the level of electrical activity present in a healthy eye, stimulating recovery in diseased or dormant cells. Electrical stimulation is known to release retinal neuroprotective factors protecting against photoreceptor cell death, raise ATP synthesis (needed for energy metabolism, membrane viability and waste management), improve microvascular circulation, and improve nerve conduction and velocity. Studies have shown that micro-current stimulation can improve vision for 85% of patients suffering from macular degeneration, 83% of those suffering from Stargardt's disease, and 66% of those suffering from retinitis pigmentosa.
Market / Customers
Macular degeneration (MD) is a major cause of eyesight deterioration in older age groups, affecting millions of people. It is estimated that 5% of the world's population will develop a form of MD. Currently there are no FDA approved treatments for Dry AMD or retinitis pigmentosa. The untreated U.S. market for Dry AMD includes over 7 million people; the aging of the baby boomer generation will lead to an estimated 50% increase in the prevalence of age-related degenerative eye diseases by 2020. Penetration of 5% into the large American market would yield $3.2 billion in associated revenues.
Competitors / Substitutes / Alternatives
Other than the ScyFIX 700, there are no device treatments or cures for Retinitis Pigmentosa and Dry Macular Degeneration
Strategy
Build distribution outside the US in Europe, Asia, South America and Canada during the balance of 2009 and 2010; while awaiting US FDA approval
Funding
Owners and private individuals
Status
The ScyFIX 700 is approved for use in Europe, and the regulatory requirements for Canada have been met as well. ScyFix anticipates receiving FDA approval for the use of micro-current neuromodulation/stimulation to treat dry macular degeneration and retinitis pigmentosa sometime between the third quarter of 2009, and Q1 2010.


2010-09-02-6958